Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:item
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Trelstar
|
| gptkbp:activities |
agonist of gonadotropin-releasing hormone receptors
|
| gptkbp:appointed_by |
gptkb:fragrance
injection |
| gptkbp:approves |
gptkb:legislation
gptkb:1988 gptkb:Australia gptkb:United_States gptkb:Native_American_tribe |
| gptkbp:clinical_trial |
Phase II
Phase III Phase I fertility treatments hormone-sensitive cancers pain management in endometriosis puberty suppression |
| gptkbp:contraindication |
pregnancy
breastfeeding hypersensitivity to buserelin |
| gptkbp:developed_by |
gptkb:temple
|
| gptkbp:formulation |
lyophilized powder
solution for injection nasal spray solution |
| https://www.w3.org/2000/01/rdf-schema#label |
buserelin
|
| gptkbp:ingredients |
C60 H78 N16 O13
|
| gptkbp:interacts_with |
anticoagulants
hormonal therapies CY P450 inducers |
| gptkbp:is_atype_of |
L02 A E01
|
| gptkbp:is_used_for |
treatment of prostate cancer
treatment of precocious puberty treatment of endometriosis |
| gptkbp:lifespan |
3-4 hours
|
| gptkbp:manager |
subcutaneous
intramuscular |
| gptkbp:marketed_as |
Buserelean
Suprefact |
| gptkbp:related_to |
gptkb:leuprolide
gptkb:triptorelin nafarelin |
| gptkbp:rounds |
hepatic
renal |
| gptkbp:side_effect |
weight gain
mood changes hot flashes decreased libido |
| gptkbp:storage |
room temperature
protected from light |
| gptkbp:type_of |
57773-63-4
|